NO20071052L - Fremgangsmater for behandling av proliferative hudsykdommer ved bruk av karbazolderivater - Google Patents

Fremgangsmater for behandling av proliferative hudsykdommer ved bruk av karbazolderivater

Info

Publication number
NO20071052L
NO20071052L NO20071052A NO20071052A NO20071052L NO 20071052 L NO20071052 L NO 20071052L NO 20071052 A NO20071052 A NO 20071052A NO 20071052 A NO20071052 A NO 20071052A NO 20071052 L NO20071052 L NO 20071052L
Authority
NO
Norway
Prior art keywords
treatment
methods
proliferative skin
skin diseases
carbazole derivatives
Prior art date
Application number
NO20071052A
Other languages
English (en)
Inventor
Robert L Hudkins
Samuel R Denmeade
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20071052L publication Critical patent/NO20071052L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår en metode for behandling av en proliferativ hudsykdom, omfattende administrering av en terapeutisk effektiv mengde av en trk-inhibitor, derav inkludert forbindelser med følgende formel:
NO20071052A 2004-09-10 2007-02-23 Fremgangsmater for behandling av proliferative hudsykdommer ved bruk av karbazolderivater NO20071052L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60920304P 2004-09-10 2004-09-10
US11/222,409 US20060058250A1 (en) 2004-09-10 2005-09-08 Methods of treating proliferative skin diseases using carbazole derivatives
PCT/US2005/032489 WO2006031772A1 (en) 2004-09-10 2005-09-09 Methods of treating proliferative skin diseases using carbazole derivatives

Publications (1)

Publication Number Publication Date
NO20071052L true NO20071052L (no) 2007-04-03

Family

ID=36034857

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071052A NO20071052L (no) 2004-09-10 2007-02-23 Fremgangsmater for behandling av proliferative hudsykdommer ved bruk av karbazolderivater

Country Status (14)

Country Link
US (1) US20060058250A1 (no)
EP (1) EP1786418A1 (no)
JP (1) JP2008512497A (no)
KR (1) KR20070113186A (no)
AR (1) AR050930A1 (no)
AU (1) AU2005285007A1 (no)
BR (1) BRPI0515115A (no)
CA (1) CA2577024A1 (no)
IL (1) IL181003A0 (no)
MX (1) MX2007002532A (no)
MY (1) MY156431A (no)
NO (1) NO20071052L (no)
TW (1) TW200621266A (no)
WO (1) WO2006031772A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
JP4405667B2 (ja) * 1997-12-31 2010-01-27 セフアロン・インコーポレーテツド Ｋ−２５２ａの３’−エピマー誘導体
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1309721A2 (en) * 2000-08-11 2003-05-14 Cephalon, Inc. Modulating multiple lineage kinase proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
AU2005285007A1 (en) 2006-03-23
AR050930A1 (es) 2006-12-06
TW200621266A (en) 2006-07-01
WO2006031772A1 (en) 2006-03-23
IL181003A0 (en) 2007-07-04
EP1786418A1 (en) 2007-05-23
KR20070113186A (ko) 2007-11-28
MY156431A (en) 2016-02-26
JP2008512497A (ja) 2008-04-24
MX2007002532A (es) 2007-05-09
US20060058250A1 (en) 2006-03-16
CA2577024A1 (en) 2006-03-23
BRPI0515115A (pt) 2008-07-01

Similar Documents

Publication Publication Date Title
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
MX2012002761A (es) Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
EA201890903A9 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
EA201691142A1 (ru) Ингибиторы мек и способы их применения
EA201101507A1 (ru) Способы лечения солидных опухолей
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
ATE517882T1 (de) Chinolinderivate
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
EA200801245A1 (ru) [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
DE602004015810D1 (de) Substituierte isochinolinderivate und anwendungsverfahren
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO330888B1 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling av slike, terapeutisk preparatinneholdende slike samt anvendelse av slike for fremstilling av preparat for behandling av sykdom
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
WO2006118973A3 (en) Methods of using heterobyclic compounds for treatment of rectal cancer
NZ597866A (en) Therapeutic lactams
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application